Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Search

You can search for specific diseases or conditions in our Clinical Trials list (the page takes about a minute to load due to the quantity of trials).

Page through all School of Medicine clinical and research trials below, or click here to look for specific types of trials.
(It will take a few seconds to load) There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 104.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 104.
Type 2 Diabetes and Exercise Research Study
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
9/22/2014
Volunteers with Chronic Kidney Disease needed for a Uric Acid Lowering Research Study
To understand the effect of lowering serum uric acid levels on vascular function in individuals with CKD by comparing Allopurinol therapy and a placebo.
Persons 18+ with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates  between 30-60 mL/min/1.73m2
9/22/2014
Are you a woman between the ages of 40 & 52
To study the effects of medication on perimenopausal symptoms.​
Women 40-52 who have regular periods and any hot flashes, cyclical bloating, mood changes, headaches or trouble sleeping
9/22/2014
Research Study: "Anxiety Risk in Teens"
To learn more about risk factors for anxiety in adolescents with cyclic vomiting syndrome.
Adolescents 13-18 who have been diagnosed with either an anxiety disorder or cyclic vomiting syndrome
9/22/2014
Are you interested in learning about how your breast milk helps your baby grow?
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
9/22/2014
Free Family Therapy for Youth with Mood Problems
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. Must agree not to participate in family therapy with another provider for the first year.
9/22/2014
Genital Herpes?
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
18+ years of age; have developed an outbreak of genital herpes within the last 10 days.
9/22/2014
Seeking Children Ages 3 to 17 with NO History of Allergies, Eczema or Asthma
The goal of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Between the ages of 3-17 No history of allergies, eczema or asthma
9/22/2014
Induction of Labor at 39 Weeks Pregnant versus Expectant Management
Pregnant women are invited to participate in a research study which plans to learn more about whether coming to the hospital and having your labor started with medicine (ie., labor induction) at 39 weeks of pregnancy can improve the baby's health at birth when compared with waiting for labor to start on its own.
First pregnancy (no previous pregnancy beyond 20 weeks) Single baby (not twins or triplets) Planning to deliver vaginally and are at least 34 weeks pregnant Plan to deliver at University of Colorado Hospital or Denver Health Hospital
9/22/2014
Pregnant Participants Needed: A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus (GBS) Vaccine in Healthy Pregnant Women
Pregnant women are invited to participate in a research study which plans to learn about antibody (substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the GBS vaccine between 24-34 6/7 weeks of their current pregnancy.  the study will also look at antibody levels in mother's breast milk.
Healthy pregnant woman 18-40 years of age 24 0/7 through 34 6/7 weeks pregnant Planning to breastfeed for at least 90 days after delivery Plan to deliver at University of Colorado Hospital
9/22/2014
Healthy Volunteers Needed
The Department of Neurology is looking for healthy volunteers to participate in a research study examining blinking and spasms in people with Blepharospam compared to healthy controls
- Between the ages of 50-80 - Must not have any metal in your body - In good general health
9/22/2014
Healthy Volunteers Needed for a research study of drug levels in blood and hair.
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Subject is age 18 to 50 years Subject is ambulatory Subject is able to comply with directly observed dosing procedures, including use of audio-visual streaming technology Subject is able to give informed consent Subject has a minimum scalp hair length of 2 cm in the occipital region. Subject is NOT pregnant, planning to become pregnant, or currently breastfeeding Subject is low risk for HIV-1 infection Subject does NOT have any active psychiatric illness(es), social condition(s), or alcohol/drug abuse Subject does NOT have history of non-traumatic, pathologic bone fractures Subject does NOT have any medical conditions that alter red blood cell kinetics Subject does NOT have any uncontrolled medical conditions that would interfere with the study conditions Subject does NOT have contraindicated concomitant medications
9/22/2014
Overweight? Women with a BMI of 30-40 needed for a birth control research study!!
The University of Colorado School of Medicine’s Department of OB/GYN is seeking healthy volunteers for a research study of a new birth control pill.
Eligible participants must: - Have a BMI 32-40 - Be 21-35 years old - Have regular menstrual cycles
9/22/2014
Research Participants Needed
We are looking for healthy participants to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria: 1) 50-85 years of age. 2) Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 3) No neurological, vascular or cardiac problems that limit function. 4) Body mass index
9/22/2014
Do you have Parkinson's Disease?
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
9/19/2014
Do you have Atopic Dermatitis (Eczema)?
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
9/19/2014
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease.
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
9/19/2014
Are you a Non-smoking Adult between the ages of 45 and 85?
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
9/19/2014
Influenza Study
Doctors at the National Institutes of Health are conducting a research study (IRC-004) to investigate whether treating the flu decreases the amount of virus we can detect in your nose, and to understand whether the change in the amount of virus is associated with changes in your symptoms.
Volunteers may be male or female and must: -be at least 18 years old -have a history of an influenza-like illness -have an onset of illness within the past 48 hours -test positive for influenza
9/19/2014
Alterations in Lung Microbiome in Acute and Chronic HIV Infection
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
9/19/2014
Has your child been diagnosed with generalized anxiety disorder?
to study sleep and brain activity
• between the ages of 12 & 18 • diagnosed with GAD OR • not diagnosed with any psychological disorders AND who are • right-handed • without orthodontic braces • not taking sleep medications
9/19/2014
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 18 years old -You do NOT have Rheumatoid Arthritis (RA)
9/19/2014
Restoring Insulin Secretion (RISE)
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
9/19/2014
Participate in a Research Study at the University of Colorado. UC Denver is Conducting a Study on Back Pain and Spinal Manipulation at the Anschutz Medical Campus
To study muscle activity during chiropractic spinal manipulations
1) 18-55 years of age 2) Male 3) Must have low back pain
9/19/2014
Have you experienced a preterm birth?
If you participate, the information we learn from you will help us better understand how and why 1 out of 10 pregnancies in the US end in preterm birth.
1. Women ages 18-45 years old 2. willing to meet for 1-2 hours in a focus group setting 3. a mother of a baby who was born more than 3 weeks before your due date
9/19/2014
Do You Smoke?
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
9/19/2014
Parents or Legal Guardians of Children with Disabilities
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
9/19/2014
The Influence of Couples' Conversation on the Heart
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
9/19/2014
Help Us Learn About Schizophrenia!
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
9/19/2014
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
9/18/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System. Sponsor Protocol # 09-07. WIRB Protocol # 20131128
Pollyea, Daniel13-2064
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. Sponsor Protocol No. CMX001-301. WIRB Protocol No. 20131501
Gutman, Jonathan13-2441
A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML). Sponsor Protocol No. M14-212. WIRB Protocol No. 20131839
Pollyea, Daniel13-2463
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer. Sponsor Protocol No. I4J-MC-HHBB(e). WIRB Protocol No. 20101374
Lewis, Karl13-2557
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab Patients with Advanced Melanoma. Sponsor Protocol No. 006. WIRB Protocol No. 20130483
Gonzalez, Rene13-2581
Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma. Sponsor Protocol No. 09-12. WIRB Protocol No. 20132209
Jimeno, Antonio13-2591
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment. Sponsor Protocol No. 1042-0603. WIRB Protocol No. 20131531
Strom, Laura13-2603
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies. Sponsor Protocol No. 52M51-001. WIRB Protocol No. 20121889
Gore, Lia13-2642
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886)(Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT-1). Sponsor Protocol No. D1532C00079. WIRB Protocol No. 20131837
Oton, Ana13-2647
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma. Sponsor Protocol No. ARRAY-520-216. WIRB Protocol No. 20131633
Smith, Clayton13-2932
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant. Sponsor Protocol No. C31001. WIRB Protocol No. 20132212
Diamond, Jennifer13-2999
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
GORE® HELEX® Septal Occluder/GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO). Sponsor Protocol No. HLX 06-03. WIRB Protocol No. 20080907
Kim, Michael13-3034
A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure. Sponsor Protocol No. HW004-A. WIRB Protocol No. 20131526
Cleveland, Joseph13-3039
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Sponsor Protocol No. GS-US-292-0119. WIRB Protocol No. 20131690
Campbell, Thomas13-3072